BiotechTube

Jynneos + MVA-BN (Quail)

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Monkeypox (Mpox)

Conditions

Monkeypox (Mpox)

Trial Timeline

Oct 27, 2025 → Oct 31, 2026

NCT ID
NCT07199569

About Jynneos + MVA-BN (Quail)

Jynneos + MVA-BN (Quail) is a phase 2 stage product being developed by Bavarian Nordic for Monkeypox (Mpox). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07199569. Target conditions include Monkeypox (Mpox).

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07199569Phase 2Recruiting

Competing Products

5 competing products in Monkeypox (Mpox)

See all competitors
ProductCompanyStageHype Score
BNT166aBioNTechPhase 1/2
38
BNT166aBioNTechPhase 2
49
MVA-BNBavarian NordicPhase 2
49
MVA-BN standard regimen + MVA-BN half-dose regimenBavarian NordicPhase 3
74
JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation)Bavarian NordicPhase 3
74

Other Products from Bavarian Nordic

IMVAMUNE®Approved
82
VAXCHORA (Cholera Vaccine, Live, Oral)Approved
82
PROSTVAC-V + PROSTVAC-F + GM-CSF + PlaceboPhase 3
74
PXVX0200 + placeboPhase 3
74
MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)Phase 3
74